Related Experiment Videos
Mexiletine: biphasic action on convulsive seizures in rodents
Abstract:
Mexiletine, an antiarrhythmic drug, exerted a protective effect in mice against convulsive seizures induced by electroshock or the chemical convulsant, pentylenetetrazol, and against seizures induced in inbred audiosusceptible mice by a sound signal. Administered in large doses, mexiletine produced a hyperkinetic myoclonic syndrome of 30-60 min duration. The hyperkinesia could be controlled by dimethylaminoethanol, phenobarbital and by an experimental anticonvulsive agent, eboracin.
Insights
Mexiletine, an antiarrhythmic drug, showed protective effects against various seizures in mice. High doses caused a temporary hyperkinetic syndrome, manageable with other agents.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Mexiletine is an antiarrhythmic medication.
- Seizure disorders represent a significant neurological challenge.
Purpose of the Study:
- To investigate the anticonvulsant properties of mexiletine.
- To evaluate the effects of mexiletine on induced seizures in a murine model.
Main Methods:
- Mice were subjected to electroshock or pentylenetetrazol-induced seizures.
- Audiogenic seizures were induced in susceptible mice.
- Effects of mexiletine and other agents were observed.
Main Results:
- Mexiletine demonstrated protective effects against electroshock, pentylenetetrazol, and audiogenic seizures.
- High doses of mexiletine induced a transient hyperkinetic myoclonic syndrome.
- Dimethylaminoethanol, phenobarbital, and eboracin mitigated mexiletine-induced hyperkinesia.
Conclusions:
- Mexiletine possesses anticonvulsant properties.
- The hyperkinetic side effect is dose-dependent and reversible.
- Further research into mexiletine's neurological effects is warranted.